FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease Enjaymo is the only approved treatment to decrease the need for red blood cell ...

FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. News release. February 4, 2022.

DEAR DR. ROACH: What are the symptoms for cold agglutinin disease, and how is it diagnosed? — P.W. ANSWER: Cold agglutinin disease is a specific type of anemia where antibodies attack and ...

The Food and Drug Administration (FDA) has granted Priority Review for the Biologics License Application (BLA) for sutimlimab (Sanofi) for the treatment of hemolysis in adult patients with cold ...

Study: Cold agglutinin anti-I antibodies in two patients with COVID-19.Image Credit: Kira_Yan/Shutterstock Background. CAS have been detected previously among individuals infected with Mycoplasma ...

Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.

Cold agglutinin disease (CAD), a rare hemolytic anemia, is mediated by auto IgM antibodies that generally have a thermal amplitude below core body temperature.

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...

I’m going to throw this open. I’ll start with Dr Jeremy Gleeson, but then I want to bring our clinical folks in. What do you think are the pain points in the management of cold agglutinin disease?

Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a person’s own red blood cells. Unlike the usual type of autoimmune hemolytic (“hemolytic” means ...

Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis Contacts Bioverativ Inc. Tracy Vineis, +1 781-663-4376 media@bioverativ.com ...

The regimen used to treat chronic cold agglutinin disease in several case studies [4,5,6,7,8,9] and in 1 small trial was 375 mg/m 2 weekly for 4 doses. References Medscape Pharmacists. 2002;3(2 ...